AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
For people on or considering these drugs, the findings could affect prescribing patterns and coverage decisions over time.
Adults with Crohn's disease or ulcerative colitis, patients on or considering biologic/JAK therapy, clinicians treating IBD, and researchers or payers following real-world effectiveness and formulary positioning.
What To Know
AbbVie presented new long-term clinical and real-world data for its gastroenterology portfolio (SKYRIZI and RINVOQ) at DDW 2026. The article summarizes investor-focused analysis of reported benefits such as sustained patient persistence, reduced steroid use, improved quality of life, and lower hospital/emergency visits for patients on these therapies.
It also notes regulatory and market milestones (e.g., subcutaneous induction filing for SKYRIZI) and discusses implications for payer decisions and formulary positioning. The piece is an investor-oriented summary of DDW data rather than a clinical report.
It highlights that real-world evidence and longer-term outcomes were presented for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) in Crohn's disease and ulcerative colitis, and suggests these data could affect prescribing, payer coverage, and AbbVie's market position.
It does not provide detailed study methods, patient counts, or specific efficacy/safety results. If you want to learn more: look for the original DDW abstracts or peer-reviewed reports referenced by AbbVie for full clinical details, and check guideline or regulatory updates before considering changes to care.
This is an investor-facing summary referencing DDW presentations; it does not replace reading original study abstracts or regulatory filings. Reported real-world benefits and regulatory filings (e.g., subcutaneous induction for SKYRIZI) require confirmation in full data releases and guideline updates before changing clinical care.
